Plasma GLP1 and Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

The Association of Plasma Levels of GLP1 With Prognosis of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02846168

Enrollment

200

Registered

2016-07-27

Start date

2016-04-30

Completion date

2017-12-31

Last updated

2016-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Angiography, Glucagon-Like Peptide 1

Brief summary

The purpose of this study is to evaluate the predicting role of plasma GLP1 level on major adverse cardiovascular events (MACE) in patients with acute myocardial infarction who undergo percutaneous coronary intervention.

Detailed description

Acute myocardial infarction (AMI) is associated with high mortality and its prognosis differed among patients. Primary percutaneous coronary intervention (pPCI) is an effective method to treat AMI. To accurately predict adverse outcomes following pPCI in patients with AMI will help doctors develop precise therapeutic strategy in advance. At present how to predict adverse events before pPCI is still controversial. In our previous studies, the investigators found that glucagon like peptide -1 (GLP-1) can improve cardiac function in patients with AMI after PCI, other studies have reported that plasma GLP-1 levels is negatively correlated with CK-MB in patients with AMI, but the relationship between plasma GLP1 and prognosis of AMI patients after PCI has not been reported, the investigators hypothesized that plasma levels of GLP1 is associated with major adverse cardiovascular events (MACE) after pPCI. The investigators planned to evaluate the predicting role of plasma GLP1 level on major adverse cardiovascular events (MACE) in patients with acute myocardial infarction who undergo percutaneous coronary intervention.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients were eligible if they were 18 years or older and presented within 12 h from the onset of symptoms and signs of acute myocardial infarction to the catheterization laboratory.

Exclusion criteria

* Taking drugs of GLP-1 analogue and DPP4 inhibitor * Cancer patients

Design outcomes

Primary

Measure	Time frame
major adverse cardiovascular events (MACE) after 6 months	at 6 months

Secondary

Measure	Time frame	Description
left ventricular ejection fractions	at 3 months	measured by transthoracic echocardiography at 3 months .

Countries

China

Contacts

Primary ContactJing-Wei Li, PhD

jingwei6829@sina.com+8610-55499309

Outcome results